1xbet 등록., Ltd.
Click 1xbet 등록rapeutics, Inc.

Approach combines Otsuka's expertise in developing 1xbet 등록 commercializing treatments for mental health with Click's record of discovering 1xbet 등록 validating digital technologies as prescription medical treatments

Otsuka Pharmaceutical Co., Ltd. announces that its U.S. holding company subsidiary Otsuka America, Inc, and Click Therapeutics, Inc. ("Click") have signed a collaboration agreement for 1xbet 등록 to develop and commercialize a prescription digital therapeutic for treatment of Major Depressive Disorder (MDD), with the intent to address unmet medical needs among this patient population and to improve outcomes.

This collaboration will leverage Click's demonstrated ability to discover 1xbet 등록 validate a software application 1xbet 등록 deploy it commercially, with Otsuka's expertise in developing approved prescription therapies for patients with serious mental illnesses, including Otsuka's established development 1xbet 등록 commercialization capabilities. The companies believe digital therapeutics align naturally with psychiatry 1xbet 등록 have significant potential to transform mental healthcare. Together, the companies aim to bring to market a new offering that will provide a novel treatment for patients with MDD.

Otsuka has agreed to commit capital to fully fund development of Click's novel mobile application 'CT-152' for MDD, 1xbet 등록 to commercialize this application world-wide upon achievement of regulatory approvals. Otsuka will pay Click up to million in upfront 1xbet 등록 regulatory milestone payments, along with an estimated million in development funding. An additional 2 million in commercial milestone payments are contingent upon regulatory approvals. In addition, Click will receive tiered, double-digit royalties on global sales of the software 1xbet 등록 the digital therapeutic applications that result.

"This collaboration signals Otsuka's commitment to meet patients' unmet medical needs by developing solutions far beyond medication. Our goal is to deliver evidence-based cognitive therapies to a broader population of patients with MDD than is currently feasible, due to the challenges of a shortage of mental health professionals 1xbet 등록 limited time for them to conduct cognitive therapy," said Kabir Nath, board member of Otsuka Pharmaceutical Co., Ltd. 1xbet 등록 president 1xbet 등록 CEO of its North American pharmaceutical business. "We are proud to be one of the few pharmaceutical companies that continues to invest in developing medicinal 1xbet 등록 digital products for the treatment of mental illnesses, 1xbet 등록 we are doing so by breaking down barriers 1xbet 등록 collaborating with leading therapeutic technology companies, such as Click, which share our vision."

According to the World Health Organization, depression is the leading cause of disability worldwide, and is a major contributor to the overall global burden of disease. 1xbet 등록 believe that new approaches are needed to address this condition, including pioneering ways to use technology and data in support of better patient outcomes.

"Otsuka has established itself as the leading innovator in digital medicine for psychiatry, 1xbet 등록 we are thrilled to collaborate with their clinical 1xbet 등록 commercial experts on our CT-152 digital therapeutic for the treatment of depression. This collaboration symbolizes the growing recognition that digital therapeutics are a new category of treatment with the potential to become a routine treatment option for physicians for their patients," said David Benshoof Klein, Chairman 1xbet 등록 CEO of Click. "The potential value of these treatments is clear: they provide validated tools that may be an effective treatment option to bring the power 1xbet 등록 accessibility of digital technologies for the benefit of the patient 1xbet 등록 physician. This recognition is also shared by regulators helping to build new pre-market review programs uniquely suited for digital therapeutics, while still retaining the traditional level of rigor 1xbet 등록 scrutiny that clinical studies require."

About the prescription digital therapeutic for MDD and the agreement between 1xbet 등록:

• CT-152 is a software application (app) that will leverage evidence-based cognitive therapy principles 1xbet 등록 Click's patient engagement platform to treat patients either independently or in conjunction with prescribed pharmacotherapies.
• The intent is that the app will be classified as a medical device (SaMD) 1xbet 등록 will fall under the FDA regulatory framework that supports innovation 1xbet 등록 commercialization of digital tools while protecting patient health.

About Click 1xbet 등록rapeutics

https://www.click1xbet 등록rapeutics.com/